> Detailanzeige

Herta, Toni [VerfasserIn]; Hahn, Magdalena [VerfasserIn]; Maier, Melanie [VerfasserIn]; Fischer, Janett [VerfasserIn]; Niemeyer, Johannes [VerfasserIn]; Hönemann, Mario [VerfasserIn]; Böhlig, Albrecht [VerfasserIn]; Gerhardt, Florian [VerfasserIn]; Schindler, Aaron [VerfasserIn]; Schumacher, Jonas [VerfasserIn]; Berg, Thomas [VerfasserIn]; Wiegand, Johannes [VerfasserIn]; van Bömmel, Florian [VerfasserIn]

Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection
  • Beteiligte: Herta, Toni [VerfasserIn]; Hahn, Magdalena [VerfasserIn]; Maier, Melanie [VerfasserIn]; Fischer, Janett [VerfasserIn]; Niemeyer, Johannes [VerfasserIn]; Hönemann, Mario [VerfasserIn]; Böhlig, Albrecht [VerfasserIn]; Gerhardt, Florian [VerfasserIn]; Schindler, Aaron [VerfasserIn]; Schumacher, Jonas [VerfasserIn]; Berg, Thomas [VerfasserIn]; Wiegand, Johannes [VerfasserIn]; van Bömmel, Florian [VerfasserIn]
  • Erschienen: Basel: MDPI, [2023]
  • Erschienen in: Pathogens ; 11, (2022)
  • Sprache: Englisch
  • Schlagwörter: treatment response ; tenofovir disoproxil fumarate ; bulevirtide ; hepatitis delta
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Background: The hepatitis B and D virus (HBV/HDV) hepatocyte entry inhibitor bulevirtide (BLV) has been available in Europe since July 2020, after the registrational trial MYR202. Real-lifedata on the efficacy and safety of BLV are sparse. Methods: We have analysed the course of treatmentwith BLV (2 mg/day) plus tenofovir disoproxil fumarate (TDF) (245 mg/day) in patients with chronichepatitis delta (CHD). Virologic (≥2 log reduction in HDV RNA or suppression of HDV RNA belowthe lower limit of detection) and biochemical (normalisation of serum ALT) treatment responses after24 weeks were defined according to the MYR202 trial. Results: Seven patients were recruited (fourwith liver cirrhosis Child–Pugh A). After 24 weeks, a virologic response was observed in five of sevenand a biochemical response was seen in three of six patients with elevated serum ALT at baseline.Extended treatment data > 48 weeks were available in three cases: two presented with continuousvirologic and biochemical responses and in one individual an HDV-RNA breakthrough was observed.Adverse effects were not recorded. Conclusions: The first real-life data of the approved dosage of2 mg of BLV in combination with TDF confirm the safety, tolerability, and efficacy of the registrationaltrial MYR202 for a treatment period of 24 weeks and beyond.
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Namensnennung (CC BY)